论文部分内容阅读
目的观察BSD2000相控阵聚焦深部热疗联合多西他赛+顺铂(TP)方案化疗治疗晚期卵巢癌的临床效果。方法将39例晚期卵巢癌患者随机分为两组,治疗组20例,给予BSD2000相控阵聚焦深部热疗+TP方案化疗;对照组19例,给予TP方案化疗。结果治疗组病灶的客观有效率(RR)高于对照组(90.0%vs 62.2%,P<0.05)。治疗组腹水的RR高于对照组(55.0%vs 21.1%,P<0.05)。治疗组生活质量评分改善率为70.0%,对照组改善率为31.6%,两组比较差异有统计学意义(P<0.05)。治疗组与对照组的1年生存率分别为77.8%和66.7%,2年生存率分别为55.5%和44.4%,两组1年和2年生存率比较差异无统计学意义(P均>0.05)。两组患者不良反应发生率的差异无统计学意义(P>0.05)。结论 BSD2000相控阵聚焦深部热疗联合TP方案化疗可以提高晚期卵巢癌的客观有效率、改善生活质量,不良反应可耐受。
Objective To observe the clinical effect of BSD2000 phased array focused deep hyperthermia combined with docetaxel + cisplatin (TP) regimen in the treatment of advanced ovarian cancer. Methods Thirty-nine patients with advanced ovarian cancer were randomly divided into two groups. The treatment group was given 20 cases BSD2000 phased array focused deep hyperthermia + TP regimen. The control group was given TP regimen. Results The objective effective rate (RR) of the treatment group was higher than that of the control group (90.0% vs 62.2%, P <0.05). The RR of ascites in the treatment group was higher than that in the control group (55.0% vs 21.1%, P <0.05). The improvement rate of quality of life score was 70.0% in treatment group and 31.6% in control group, the difference was statistically significant (P <0.05). The 1-year survival rates of the treatment group and the control group were 77.8% and 66.7%, respectively, and the 2-year survival rates were 55.5% and 44.4% respectively. There was no significant difference in the 1-year and 2-year survival rates between the two groups (P> 0.05 ). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion BSD2000 phased array focused deep hyperthermia combined with TP regimen chemotherapy can improve the objective and effective rate of advanced ovarian cancer, improve quality of life, adverse reactions can be tolerated.